THE PURPOSE of this study was to observe the effects of a new anticonvulsant called Mysoline in a series of 30 epileptic patients treated in the outpatient department of the neurological service of the Mount Sinai Hospital.
In 1952 Bogue and Carrington1 introduced a new anticonvulsant drug, now known as Mysoline. Chemically, this drug, which is closely related to phenobarbital, is 5-phenyl-5-ethyl-hexahydropyrimidine-4,6-dione. Its formula and its close relationship to phenobarbital are apparent in the figure. It is a white, stable, crystalline
substance, practically tasteless and only lightly soluble in water. It has been described by these authors as having an extremely low toxicity in all species of laboratory animals tested, including monkeys. Mysoline is prescribed in tablet form, each tablet containing 250 mg. of the drug. The daily doses employed in our series of epileptic patients varied from 0.5 to 2.0 gm.
Of the 30 patients, only 2 were
GREENSTEIN L, SAPIRSTEIN MR. TREATMENT OF EPILEPSY WITH MYSOLINE. AMA Arch NeurPsych. 1953;70(4):469–473. doi:10.1001/archneurpsyc.1953.02320340059005
Customize your JAMA Network experience by selecting one or more topics from the list below.